Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies-Reference-Cited by-同舟云学术

Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies

Published:2018-11-26 Issue:2 Volume:115 Page:266-276
ISSN:0008-6363
Container-title:Cardiovascular Research
language:en
Short-container-title:

Author:

Chin Ken Lee¹,Ofori-Asenso Richard¹,Hopper Ingrid¹,von Lueder Thomas G¹²,Reid Christopher M¹³,Zoungas Sophia⁴⁵,Wang Bing H¹,Liew Danny¹

Affiliation:

1. Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia

2. Department of Cardiology, Oslo University Hospital, Oslo, Norway

3. School of Public Health, Curtin University, Perth, Australia

4. Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

5. The George Institute for Global Health, Sydney, Australia

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

http://academic.oup.com/cardiovascres/article-pdf/115/2/266/27708786/cvy295.pdf

Reference73 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015